Processa Pharmaceuticals Reports Promising Phase 2 Data for NGC-Cap Combination in Metastatic Breast Cancer
核心洞察
Preliminary Phase 2 data from 16 patients show that NGC-Cap (PCS6422 plus capecitabine) significantly increases exposure to cancer-killing metabolites while maintaining comparable safety to standard capecitabine monotherapy.
Patients receiving NGC-Cap demonstrated up to ten times lower exposure to FBAL (搜索), a toxic metabolite associated with hand-foot syndrome (搜索), with only mild Grade 1 symptoms compared to more severe Grade 2 symptoms in the monotherapy group.
The company plans to complete enrollment for a formal 20-patient interim analysis by the end of Q1 2026, with full efficacy and safety data expected in early 2026.
Processa Pharmaceuticals has released encouraging preliminary Phase 2 data for NGC-Cap, its combination therapy of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer (搜索). The data from the first 16 of 19 enrolled patients demonstrate that NGC-Cap significantly increases exposure to capecitabine's cancer-killing metabolites without increasing the severity of side effects compared to standard capecitabine monotherapy.
Enhanced Metabolite Profile Shows Therapeutic Promise
The preliminary findings indicate that NGC-Cap achieves a differentiated pharmacologic profile that could meaningfully improve the therapeutic index of capecitabine-based therapy. According to Dr. David Young, President of Research and Development at Processa, "NGC-Cap appears to meaningfully increase exposure to the capecitabine metabolites responsible for killing cancer cells, while reducing exposure to the catabolite metabolites associated with dose-limiting toxicity such as hand-foot-syndrome (HFS)."
In the ongoing randomized study, 19 patients have been assigned to receive either NGC-Cap (150 mg twice daily) or standard-dose capecitabine monotherapy (1,000 mg/m² twice daily). The evaluation focused on safety data from the first 16 patients, with data from all 19 patients not yet available for this preliminary analysis.
Reduced Toxicity Profile Despite Increased Activity
A key finding from the study involves the formation of FBAL (搜索), a catabolite metabolite associated with hand-foot syndrome (搜索). Patients receiving NGC-Cap demonstrated substantially lower exposure to FBAL—up to ten times less than with capecitabine monotherapy. This reduction translated into clinically meaningful differences in toxicity severity.
While the number of patients reporting hand-foot syndrome (搜索) was similar between treatment groups, patients in the NGC-Cap arm experienced only mild Grade 1 symptoms, compared to patients receiving capecitabine monotherapy who experienced symptoms of greater severity, up to Grade 2.
As expected with increased exposure to active metabolites, a greater proportion of patients receiving NGC-Cap experienced side effects related to capecitabine's cancer-killing metabolites, and the total number of such side effects per patient was higher compared to patients receiving capecitabine alone. However, the severity of these side effects remained similar between treatment arms, indicating that the increased activity did not translate into more severe toxicity.
Next Generation Cancer Platform Validation
The results support Processa's Next Generation Cancer (NGC) strategy, which focuses on modifications of existing FDA-approved oncology therapies to alter their metabolism and distribution while maintaining existing cancer-killing mechanisms. George Ng, Chief Executive Officer of Processa Pharmaceuticals, stated, "We believe NGC-Cap continues to demonstrate a differentiated pharmacologic profile that could meaningfully improve the therapeutic index of capecitabine-based therapy."
NGC-Cap is designed to increase systemic exposure to active cancer-killing anabolite metabolites while reducing formation of toxic catabolite metabolites. This approach aims to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory pathway.
Clinical Timeline and Future Milestones
Processa anticipates completing enrollment of the final patient in the formal 20-patient interim analysis by the end of the first quarter of 2026, in accordance with the trial protocol. The full interim analysis, which will include both efficacy and safety data from the first 20 patients enrolled in the study, is expected in early 2026.
Dr. Young noted that the observed distribution and severity of side effects align closely with pharmacologic expectations, being "consistent with enhanced exposure to active cancer-killing metabolites and reduced formation of catabolites, including FBAL (搜索)."
The company views this program as a key value driver and an important opportunity for patients with advanced or metastatic breast cancer (搜索), believing that the balance between potential efficacy and tolerability is central to improving outcomes in this patient population.